Based on the key indicators related to Acurx Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Acurx Pharmaceuticals LLC is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Acurx Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 03/25/2025, Other Stockholder Equity is likely to grow to about 71.3 B, though Retained Earnings are likely to grow to (64 B). Key indicators impacting Acurx Pharmaceuticals' financial strength include:
Investors should never underestimate Acurx Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Acurx Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Acurx Pharmaceuticals LLC.
Net Income
(13.4 Billion)
Acurx
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Common Stock
Other Assets
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Acurx Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Acurx Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Acurx Pharmaceuticals' assets may result in an increase in income on the income statement.
Acurx Pharmaceuticals competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, and AN2 Therapeutics. Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York. Acurx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Acurx Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Acurx Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Acurx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Acurx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acurx Pharmaceuticals competition to find correlations between indicators driving Acurx Pharmaceuticals's intrinsic value. More Info.
Acurx Pharmaceuticals LLC is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Acurx Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Acurx Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Acurx Pharmaceuticals LLC Systematic Risk
Acurx Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Acurx Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Acurx Pharmaceuticals LLC correlated with the market. If Beta is less than 0 Acurx Pharmaceuticals generally moves in the opposite direction as compared to the market. If Acurx Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Acurx Pharmaceuticals LLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Acurx Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Acurx Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Acurx Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Acurx Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Acurx Pharmaceuticals growth as a starting point in their analysis.
Acurx Pharmaceuticals March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Acurx Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Acurx Pharmaceuticals LLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Acurx Pharmaceuticals LLC based on widely used predictive technical indicators. In general, we focus on analyzing Acurx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acurx Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.